Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AQ280 in Healthy Subjects
NCT05485779Phase 1Completed
- Sponsor
- Aqilion
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AQ280 in eosinophilic esophagitis (EoE) (8 arms), sponsored by Aqilion. Primary endpoints: Treatment Emergent Adverse Events at Day 14, Clinically Significant Abnormalities in Vital Signs at Day 14 and 2 more. Started Jul 2022; status: completed.
02
Drugs
AQ280
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05485779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485779.